This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS) (ACT-RCT-C 01)

This study has been completed.
Information provided by:
Schwabe-Wenex International Ltd Identifier:
First received: May 4, 2008
Last updated: September 30, 2009
Last verified: September 2009
To compare the efficacy and safety of Agnucaston tablets with placebo for the treatment of Premenstrual Syndrome (PMS) and assess if Agnucaston tablets are superior to placebo on efficacy or not.

Condition Intervention Phase
Premenstrual Syndrome Drug: extracts of Vitex agnus castus tablets Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Schwabe-Wenex International Ltd:

Primary Outcome Measures:
  • Change from baseline (cycle 0) of premenstrual complaints, assessed by the sum score of the 18 items of the PMS-Diary, after 3 cycles under treatment, evaluated for the luteal phase, i.e. the last 7 days prior a menstrual bleeding. [ Time Frame: the last 7 days prior a menstrual bleeding ]

Secondary Outcome Measures:
  • Change from baseline (cycle 0) of the sum score of the 36 questions of the PMTS self-assessment scale after 3 cycles under treatment. [ Time Frame: on the 1st-3nd day of menstrual bleeding ]

Enrollment: 217
Study Start Date: February 2005
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: extracts of Vitex agnus castus tablets
orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
Other Name: Agnucaston tablets
Placebo Comparator: 2 Drug: Placebo

Detailed Description:
Premenstrual syndrome (PMS) is a common disorder in women and consists of somatic and/or behavioral/mood symptoms, which can impair a woman's social and work-related functioning. Some clinical studies with preparations containing Vitex agnus castus have demonstrated a positive effect on PMS with good tolerability. The aim of this clinical trial is to investigate the efficacy and safety of Agnucaston tablets for the therapy of PMS.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of PMS disease
  • Age between 18 and 45 years
  • Patients is in general good health

Exclusion Criteria:

  • Any of the following endocrinological diseases: diabetes mellitus, hypo-/hyperthyreosis, pituitary tumor.
  • Clearly kidney or liver disease, abnormal kidney or liver function.
  • Any of the following gynecological diseases: endometriosis, mammary carcinoma, intraductal papilloma, galactorrhea, mammary fibroadenoma.
  • Prior to the start of the study any planned surgical intervention of the breasts (including cyst puncture), of the uterus and/ or adnexa.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00672607

Peking Union Medical College Hospital
Beijing, China, 100730
Sponsors and Collaborators
Schwabe-Wenex International Ltd
  More Information

Responsible Party: Helen Guo, Schwabe-Wenex Identifier: NCT00672607     History of Changes
Other Study ID Numbers: Schwabe-Wenex
Study First Received: May 4, 2008
Last Updated: September 30, 2009

Keywords provided by Schwabe-Wenex International Ltd:
premenstual syndrome, PMS, clinical trial

Additional relevant MeSH terms:
Premenstrual Syndrome
Pathologic Processes
Menstruation Disturbances processed this record on September 19, 2017